E2F-1 inhibits ferroptosis in osteosarcoma cells by activating the PSAT1/Xct/GPX4 signaling axis

Abstract Osteosarcoma is a common primary malignant bone tumour that occurs mainly in children and adolescents and has a poor survival and prognosis. Currently, ferroptosis is a newly defined form of cell death, but the mechanism between it and osteosarcoma is unclear. To further investigate the relationship between osteosarcoma and ferroptosis, it is important to search for new biomolecular factors. We used bioinformatics to dig deeper into the ferroptosis gene PSAT1, which is closely associated with osteosarcoma. Although PSAT1 has been reported in other types of tumours and plays an important role in the development of many tumours, such as melanoma and breast cancer, little research has been done in the field of osteosarcoma. To explore the role of PSAT1 in osteosarcoma and its association with ferroptosis, we designed relevant experiments. Subsequently, we predicted the transcription factor E2F-1 for PSAT1 from the transcription factor frediction database and experimentally verified that E2F-1 could inhibit ferroptosis in OS cells by activating PSAT1. The results indicated that PSAT1 could promote the development of osteosarcoma and inhibit the ferroptosis process in osteosarcoma cells. This finding implies that PSAT1 may become a new target for the diagnosis and treatment of osteosarcoma in the future, bringing new breakthroughs to clinical practice.